Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.27 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.27 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management emphasized their commitment to growth and innovation. However, they did not provide any updates on future performance expectations.
Management did not provide specific guidance for the upcoming quarters.
The company remains focused on expanding its product offerings.
Veracyte's earnings report showed a loss per share, which was expected, but the stock still reacted positively, gaining 1.16%. Investors may be encouraged by the company's focus on growth and product expansion despite the lack of specific guidance. The stock's increase suggests that the market remains optimistic about Veracyte's long-term potential.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MARATHON PETE CORP
Apr 30, 2018